Latest News
Jan 10, 2018
Publication: SonoTran® Doesn’t Affect the Inherent Activity of Oncology Drugs

Oxford, UK – 10th January 2018 – OxSonics Limited, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer patients, today reported that a paper entitled “Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines” was published in the International Journal of Nanomedicine. The publication evidences the fact that ultrasound parameters used to safely and successfully deliver small molecule, antibody and viral-based oncology agents to tumors in preclinical models do not detrimentally impact on the structure or activity of these medicines. Dr. Colin Story, Chief Executive Officer commented: “The findings of these detailed experiments add to the significant body of data underpinning the company’s drug delivery platform, SonoTran®. I would like to thank our collaborators in generating this compelling evidence.”
A link to the publication is provided here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768183/

- ENDS -


About OxSonics® Limited
OxSonics® was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics® SonoTran® drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran® can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics® is based in Oxford, UK.
For more information please visit: www.oxsonics.com 

   PDF Version
© OxSonics Ltd 2016